These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36216006)

  • 1. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Mackenzie IS; Hawkey CJ; Ford I; Greenlaw N; Pigazzani F; Rogers A; Struthers AD; Begg AG; Wei L; Avery AJ; Taggar JS; Walker A; Duce SL; Barr RJ; Dumbleton JS; Rooke ED; Townend JN; Ritchie LD; MacDonald TM;
    Lancet; 2022 Oct; 400(10359):1195-1205. PubMed ID: 36216006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation.
    Mackenzie IS; Hawkey CJ; Ford I; Greenlaw N; Pigazzani F; Rogers A; Struthers AD; Begg AG; Wei L; Avery AJ; Taggar JS; Walker A; Duce SL; Barr RJ; Dumbleton JS; Rooke ED; Townend JN; Ritchie LD; MacDonald TM;
    Health Technol Assess; 2024 Mar; 28(18):1-55. PubMed ID: 38551218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
    Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study.
    Mackenzie IS; Ford I; Walker A; Hawkey C; Begg A; Avery A; Taggar J; Wei L; Struthers AD; MacDonald TM;
    BMJ Open; 2016 Sep; 6(9):e013774. PubMed ID: 27609859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
    MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
    BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.
    Mackenzie IS; Rogers A; Poulter NR; Williams B; Brown MJ; Webb DJ; Ford I; Rorie DA; Guthrie G; Grieve JWK; Pigazzani F; Rothwell PM; Young R; McConnachie A; Struthers AD; Lang CC; MacDonald TM;
    Lancet; 2022 Oct; 400(10361):1417-1425. PubMed ID: 36240838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial.
    Olthuis SGH; Pirson FAV; Pinckaers FME; Hinsenveld WH; Nieboer D; Ceulemans A; Knapen RRMM; Robbe MMQ; Berkhemer OA; van Walderveen MAA; Lycklama À Nijeholt GJ; Uyttenboogaart M; Schonewille WJ; van der Sluijs PM; Wolff L; van Voorst H; Postma AA; Roosendaal SD; van der Hoorn A; Emmer BJ; Krietemeijer MGM; van Doormaal PJ; Roozenbeek B; Goldhoorn RB; Staals J; de Ridder IR; van der Leij C; Coutinho JM; van der Worp HB; Lo RTH; Bokkers RPH; van Dijk EI; Boogaarts HD; Wermer MJH; van Es ACGM; van Tuijl JH; Kortman HGJ; Gons RAR; Yo LSF; Vos JA; de Laat KF; van Dijk LC; van den Wijngaard IR; Hofmeijer J; Martens JM; Brouwers PJAM; Bulut T; Remmers MJM; de Jong TEAM; den Hertog HM; van Hasselt BAAM; Rozeman AD; Elgersma OEH; van der Veen B; Sudiono DR; Lingsma HF; Roos YBWEM; Majoie CBLM; van der Lugt A; Dippel DWJ; van Zwam WH; van Oostenbrugge RJ;
    Lancet; 2023 Apr; 401(10385):1371-1380. PubMed ID: 37003289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial.
    Loeb M; Roy A; Dokainish H; Dans A; Palileo-Villanueva LM; Karaye K; Zhu J; Liang Y; Goma F; Damasceno A; Alhabib KF; Yonga G; Mondo C; Almahmeed W; Al Mulla A; Thanabalan V; Rao-Melacini P; Grinvalds A; McCready T; Bangdiwala SI; Yusuf S;
    Lancet Glob Health; 2022 Dec; 10(12):e1835-e1844. PubMed ID: 36400089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
    Butler CC; Yu LM; Dorward J; Gbinigie O; Hayward G; Saville BR; Van Hecke O; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Djukanovic R; Gadola S; Kirkpatrick J; de Lusignan S; Ogburn E; Evans PH; Thomas NPB; Patel MG; Hobbs FDR;
    Lancet Respir Med; 2021 Sep; 9(9):1010-1020. PubMed ID: 34329624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial.
    Schwarzbach CJ; Eichner FA; Rücker V; Hofmann AL; Keller M; Audebert HJ; von Bandemer S; Engelter ST; Geis D; Gröschel K; Haeusler KG; Hamann GF; Meisel A; Sander D; Schutzmeier M; Veltkamp R; Heuschmann PU; Grau AJ;
    Lancet Neurol; 2023 Sep; 22(9):787-799. PubMed ID: 37459876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    He J; Ouyang N; Guo X; Sun G; Li Z; Mu J; Wang DW; Qiao L; Xing L; Ren G; Zhao C; Yang R; Yuan Z; Wang C; Shi C; Liu S; Miao W; Li G; Chen CS; Sun Y;
    Lancet; 2023 Mar; 401(10380):928-938. PubMed ID: 36871573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
    Roaldsen MB; Eltoft A; Wilsgaard T; Christensen H; Engelter ST; Indredavik B; Jatužis D; Karelis G; Kõrv J; Lundström E; Petersson J; Putaala J; Søyland MH; Tveiten A; Bivard A; Johnsen SH; Mazya MV; Werring DJ; Wu TY; De Marchis GM; Robinson TG; Mathiesen EB;
    Lancet Neurol; 2023 Feb; 22(2):117-126. PubMed ID: 36549308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Blood Pressure Lowering Treatment Trialists' Collaboration
    Lancet; 2021 May; 397(10285):1625-1636. PubMed ID: 33933205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
    Kelly P; Lemmens R; Weimar C; Walsh C; Purroy F; Barber M; Collins R; Cronin S; Czlonkowska A; Desfontaines P; De Pauw A; Evans NR; Fischer U; Fonseca C; Forbes J; Hill MD; Jatuzis D; Kõrv J; Kraft P; Kruuse C; Lynch C; McCabe D; Mikulik R; Murphy S; Nederkoorn P; O'Donnell M; Sandercock P; Schroeder B; Shim G; Tobin K; Williams DJ; Price C
    Lancet; 2024 Jul; 404(10448):125-133. PubMed ID: 38857611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial.
    Barkham M; Saxon D; Hardy GE; Bradburn M; Galloway D; Wickramasekera N; Keetharuth AD; Bower P; King M; Elliott R; Gabriel L; Kellett S; Shaw S; Wilkinson T; Connell J; Harrison P; Ardern K; Bishop-Edwards L; Ashley K; Ohlsen S; Pilling S; Waller G; Brazier JE
    Lancet Psychiatry; 2021 Jun; 8(6):487-499. PubMed ID: 34000240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomised controlled trial in the Netherlands.
    Huijberts I; Pinckaers FME; Olthuis SGH; van Kuijk SMJ; Postma AA; Boogaarts HD; Roos YBWEM; Majoie CBLM; van der Lugt A; Dippel DWJ; van Zwam WH; van Oostenbrugge RJ;
    Lancet Neurol; 2024 Sep; 23(9):893-900. PubMed ID: 38909624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomised controlled trial.
    Palmer R; Dimairo M; Cooper C; Enderby P; Brady M; Bowen A; Latimer N; Julious S; Cross E; Alshreef A; Harrison M; Bradley E; Witts H; Chater T
    Lancet Neurol; 2019 Sep; 18(9):821-833. PubMed ID: 31397288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
    Kalra PR; Cleland JGF; Petrie MC; Thomson EA; Kalra PA; Squire IB; Ahmed FZ; Al-Mohammad A; Cowburn PJ; Foley PWX; Graham FJ; Japp AG; Lane RE; Lang NN; Ludman AJ; Macdougall IC; Pellicori P; Ray R; Robertson M; Seed A; Ford I;
    Lancet; 2022 Dec; 400(10369):2199-2209. PubMed ID: 36347265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.